Navigation Links
Robotic exoskeleton replaces muscle work

ived from the brain were translated into movement by the exoskeleton.

"The (artificial) muscles are pneumatic. When the computer gets the electrical signal from the (wearer's) muscle, it increases the air pressure into the artificial muscle on the brace," Ferris said. "Essentially the artificial muscle contracts with the person's muscle."

Initially the wearer's gait was disrupted because the mechanical power added by the exoskeleton made the muscle stronger. However, in a relatively short time, the wearers adapted to the new strength and used their muscles less because the exoskeleton was doing more of the work. Their gait normalized after about 30 minutes.

The next step is to test the device on patients with impaired muscle function, Ferris said.
'"/>

Source:University of Michigan


Page: 1 2

Related biology news :

1. Penn Researchers Use Robotic Surgery
2. Penn Surgeons Use Completely Robotic Surgery to Successfully Treat Prostate Cancer
3. Robotic joystick reveals how brain controls movement
4. Robotic whiskers can sense three-dimensional environment
5. Robotic therapy helps restore hand use after stroke
6. Heart repair gets new muscle
7. Small worm yields big clue on muscle receptor action
8. New complete muscle grown in the lab
9. Spiders help scientists discover how muscles relax
10. Cant serve an ace? Could be muscle fatigue
11. Lance Armstrong through a physiological lens: hard training boosts muscle power 8%
Post Your Comments:
(Date:12/4/2009)... amyloids the fibrous protein deposits associated with diseases such ... potential new area for therapeutics. , It was believed that ... known as fibres - are inert, but that there may ... and cause disease. , But in a paper published ...
(Date:12/3/2009)... co-workers discovered that specific types of human papillomavirus (HPV) ... pathogens cause cells to degenerate. It is known today ... E7. Both proteins switch off different cellular control functions, ... Rsl and his co-workers at DKFZ have now discovered ...
(Date:12/3/2009)... likened to emptying a museum of its collection, or dumping ... replacing every local cuisine with McDonald,s burgers. , But the ... the world boring. New research now suggests it may also ... , "Habitat destruction and biodiversity loss,"driven by the replacement of ...
Breaking Biology News(10 mins):New therapy targets for amyloid disease 2Papillomavirus silences innate immune response 2Species down, disease up 2Species down, disease up 3Species down, disease up 4Lives Compromised and Patient Access Limited with New Cuts to Medicare 62021 1Lives Compromised and Patient Access Limited with New Cuts to Medicare 62021 2Statement of Support 3A Strengthening Oral Health Care is Key Part of Health Reform 62018 1Statement of Support 3A Strengthening Oral Health Care is Key Part of Health Reform 62018 2Shire Submits European Marketing Authorization Application 28MAA 29 for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 14957 1Shire Submits European Marketing Authorization Application 28MAA 29 for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 14957 2Shire Submits European Marketing Authorization Application 28MAA 29 for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 14957 3
... WASHINGTON Members of the public can send their ... mission dedicated to understanding the effects of particles in ... , The "Send Your Name Around the Earth" Web ... mission and place their names in orbit for years ...
... Enhanced Applicant,Verification and New Security Features that Combat ... 25 L-1 Identity,Solutions, Inc. (NYSE: ID ... today announced that the Massachusetts Registry of Motor ... a new six-year,contract to upgrade and further enhance ...
... surrounded by the San Bernardino National Forest have taken ... to a U.S. Forest Service study completed this summer., ... A Case Study on the San Bernardino National Forest," ... surveys and focus group discussions in 2007 had taken ...
Other Biology News:Send your name around the Earth on NASA'S Glory mission 2L-1 Identity Solutions Awarded New Massachusetts RMV Driver's License Contract Valued at an Estimated $32 Million 2L-1 Identity Solutions Awarded New Massachusetts RMV Driver's License Contract Valued at an Estimated $32 Million 3Study reveals homeowner perceptions in fire-prone areas 2
(Date:12/2/2009)... Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ... dose confirmation and dosimetry trial of Cotara® in patients ... brain cancer. Cotara is a targeted monoclonal antibody ... new treatment for GBM. Cotara specifically targets cells ...
(Date:12/2/2009)... - "Bolstering Biodiversity in Africa: ... Coinciding with the International Year of Biodiversity, ... international conference in Libreville,(Gabon) on the issue of ... attended by government and state leaders, ministers,scientific experts, ...
(Date:12/2/2009)... TechConnect World, an event bringing together the ... cleantech, nanotech, biotech and MEMS, announced the December ... ,, Now in its 14th year, TechConnect World, ... Institute (NSTI), and the Clean Technology and Sustainable ...
(Date:12/2/2009)... Ltd today announced data presentations on its novel oral ... 51st Annual Meeting and Exposition in New Orleans. ,, ... the Phase 1 dose-escalation trial of SB1518 detailing its ... ranging from 100 to 600 mg. These doses were ...
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
... clinical-stage biopharmaceutical company focused on diseases of epidemic potential, ... for SQ109 with the dosing of the first cohort ... replace one or more of the current first-line antitubercular ... Fast Track designation and FDA/EMEA Orphan Drug Designation in ...
... Syrinx Consulting Corporation , an IT consulting ... SharePoint applications , announced today that ... a leading biopharmaceutical company in the Boston area. ... gigabytes of data from a SharePoint 2003 environment to ...
... biotechnology research is providing new applications for nutraceutical ... two leading health concerns among consumers. Leading ... www.advanascience.com , will present future ... consumer healthy category at VitaFoods International on Wednesday, ...
Other Biology Technology:Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109 2Syrinx Wins Contract with Leading Pharmaceutical Company for SharePoint 2007 Services 2Industry Expert Reveals Cutting Edge Biotechnology Science for Nutraceutical and Functional Food Applications 2
This antibody is specific for human J-chain as defined by ELISA assay using purified human immunoglobulin fragments as solid phase target antigen....
UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... proto-oncogene was first identified as the cellular homolog ... B and Jun D have been shown to ... regions, which are involved in dimerization and DNA ... in transcriptional activation, diverge. Antigen: ...
Biology Products: